Sorafenib stimulates NRF2 expression in HCC cells, which boosts MT-1G expression, which prevents ferroptosis by inhibiting GSH depletion, which is one of the pathways associated in sorafenib resistance (87). Here, NFE2L2 is linked to hepatocellular carcinoma.